Anatara Lifesciences Ltd (AU:ANR) has released an update.
Anatara Lifesciences is experiencing robust participant recruitment for Stage 2 of its GaRP-IBS clinical trial, which aims to address the high unmet need for effective IBS treatments. The trial has garnered over 500 expressions of interest, with 13 participants already enrolled, and it is projected to reach its target of 60-100 participants by Q3 2024. Anatara remains actively engaged with global pharmaceutical companies and is exploring additional healthcare opportunities while continuing to assess the promising potential of its GaRP product.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.
